Navigation Links
LUNGevity Foundation Praises Recent FDA Approval of New Lung Cancer Treatment Drug XALKORI® (crizotinib)
Date:8/27/2011

WASHINGTON, Aug. 27, 2011 /PRNewswire-USNewswire/ -- LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI® (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

LUNGevity Foundation President Andrea Stern Ferris called the FDA's approval of XALKORI incredibly positive, saying: "The trial results are remarkable, strengthening the body of evidence that targeted therapies hold great promise in treating this deadly cancer. Lung cancer is the nation's number one cancer killer. The federal government and the private sector need to invest in accelerating all of the other promising research now underway that can change the way we diagnose and treat lung cancer and save lives."

XALKORI is a member of a new class of drugs that work by inhibiting the anaplastic lymphoma kinase (ALK) gene. Alterations of this gene are thought to drive tumor development in certain cancers. XALKORI is approved for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.  About 10,000 of the 222,000 Americans diagnosed with non-small-cell lung cancer each year could be expected to have the genetic abnormality. William Pao, associate professor of medicine, Vanderbilt-Ingram Cancer Center, said: "The approval of crizotinib is an exciting development.  It further validates the idea that lung cancers are very different at the molecular level, even though they may look similar under the microscope, and should be treated accordingly.  It also shows how fast translational research is becoming medical practice. ALK fusions in lung cancer were only first reported in 2007, and by 2010, we already had reports on the activity of a specific ALK inhibitor in patients with ALK fusion-positive lung cancer.  Hopefully, th
'/>"/>

SOURCE LUNGevity Foundation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alzheimers Drug Discovery Foundation Supports Madera Biosciences with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
2. Enox Biopharma, Inc. Will Be Granted its Foundation Patent
3. Foundation Venture Capital Group Investment Shows Promise in Diagnosis of Alzheimers Disease Using a Drop of Blood
4. The Pulmonary Hypertension Association and MedicAlert Foundation Form Alliance to Safeguard Patients
5. Futbol Club Barcelona and the Bill & Melinda Gates Foundation Team Up to End Polio and Give Every Child an Equal Shot at Life
6. Merz Pharmaceuticals Commends The Benign Essential Blepharospasm Research Foundation On 30 Years Of Community Support
7. Lilly Donation to Patient Advocate Foundation Expands Services and Access for Patients With Most Common Form of Lung Cancer
8. Henry Schein Cares Foundation and Henry Schein Cares Contribute More Than $375,000 in Financial and Product Donations for Disaster Relief Efforts on Three Continents
9. Patient Advocate Foundation Announces Significant Operational, Technology Enhancements to Co-Pay Relief (CPR) Program
10. Amerigroup Foundation Presents Grant to Rx Partnership
11. ECRI Institute and Health Care Improvement Foundation Launch CT Radiation Safety Collaborative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... OAKS, Calif., April 13, 2011 Amgen (NASDAQ: ... first quarter financial results on Wednesday, April 20, 2011 after ... be followed by a conference call with the investment community ... Amgen will be Kevin Sharer, chairman and chief executive officer, ...
... 13, 2011 Perrigo (Nasdaq: PRGO;TASE) today announced that ... TEVA ), has received final OTC approval to sell ... tablets; the generic equivalents of Sanofi-Aventis, Allegra 60 mg ... for these products, and Teva and Sanofi-Aventis have settled ...
Cached Medicine Technology:Amgen Announces Webcast of 2011 First Quarter Financial Results 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 2Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets 3
(Date:7/9/2014)... A retrospective study conducted by researchers at Tufts University ... adults with intellectual and developmental disabilities, the likelihood of ... dental care increased. The findings, published in the July/August ... help improve interventions designed to address the oral health ... reviewed the dental records of 107 patients at one ...
(Date:7/9/2014)... , , , , , ... , , , , ... the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , , ... , , , , , ... , , , , , , University ...
(Date:7/9/2014)... of Medicine of the University of Southern California ... component of the immune system are completely resistant ... The discovery suggests that blocking this immune system ... and hyper-inflammatory diseases such as rheumatoid arthritis and ... online on June 23 in The Journal ...
(Date:7/8/2014)... The Department of Defense,s Defense Advanced Research Projects ... up to $2.5 million to develop an implantable ... stimulate neurons within the brain to help restore ... research builds on the understanding that memory is ... of the brain encode information, store it and ...
(Date:7/8/2014)... In a study published yesterday in the scientific ... Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new ... affects over 200 million people world wide. , An ... divided into small sections or ,neighborhoods., Scientists can determine ... for gene production, by looking for a marker on the ...
Breaking Medicine News(10 mins):Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2
... TORRANCE, Calif., April 27 According to new ... , supplements of Lactobacillus casei strain Shirota may ... fatigue syndrome (CFS). Thirty-nine patients with CFS ... Shirota or placebo for two months. Compared ...
... Services Department declares a Public Health EmergencyHARRISBURG, Pa., April ... working with federal officials to contain the impact of ... in the declaration of a national public health emergency ... to educate the public and health care providers of ...
... toxins in the products we use for lifestyle convenience, ... toxic load on our bodies contributing to chronic illnesses, ... awareness of our environmental exposures, Metametrix Clinical Laboratory ( ... release of three new testing profiles in the Toxic ...
... 100 Exhibits, Forums on Health Care and Financial Security, ... Top Musicians***LOS LOBOS TO HEADLINE ENTERTAINMENT***SAN ANTONIO, April 27 ... for people age 50+, today announced it will bring ... San Antonio on May 15-16. The two-day, cross-generational ...
... screen at 40, but yearly PSA may not be necessary, ... guidelines on prostate cancer screening suggest that annual PSA blood ... same guidelines call for a "baseline" PSA test at the ... (PSA) test to detect early signs of prostate cancer should ...
... WHAT: , Media may now register to attend ... Symposium of the Cardiovascular Research Foundation. TCT gathers ... world to present and discuss the latest developments ... medicine. Now in its 21st year, TCT brings ...
Cached Medicine News:Health News:New Study Shows Supplementing With Probiotics May Ease Anxiety 2Health News:Pennsylvania Working Closely With Federal Partners to Contain Impact of Swine Flu 2Health News:Pennsylvania Working Closely With Federal Partners to Contain Impact of Swine Flu 3Health News:Metametrix Announces New Toxic Effects Profiles to Help Combat Growing Concerns About Toxicity and Health 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 3Health News:Experts Back Away From Annual PSA Test 2Health News:Experts Back Away From Annual PSA Test 3Health News:Media registration now open for TCT 2009 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: